Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pentoxifylline
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Poolbeg Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate
Details : Through the agreement with Silk Road Therapeutics to acquire novel topical muco-adherent formulation of Trental (pentoxifylline), for oral ulcers in patients suffering from behcet's disease.
Brand Name : Trental
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 30, 2024
Lead Product(s) : Pentoxifylline
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Poolbeg Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Pentoxifylline
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Soligenix
Deal Size : Undisclosed
Deal Type : Agreement
Details : The option agreement grants Soligenix the right to acquire a novel topical formulation of SRT001 (pentoxifylline), a non-biological anti-TNF-alpha inhibitor, for the treatment of mucocutaneous ulcers in patient's suffering from Behçet's Disease (BD).
Brand Name : SRT001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 01, 2023
Lead Product(s) : Pentoxifylline
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Soligenix
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?